Stockreport

Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock

STEMLINE THERAPEUTICS  (STML) 
Last stemline therapeutics earnings: 3/13 04:45 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.stemline.com/investor-relations
PDF NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, [Read more]